TY - JOUR
T1 - Administration of antioxidant compounds affects the lens chaperone activity and prevents the onset of cataracts
AU - Nakazawa, Yosuke
AU - Nagai, Noriaki
AU - Ishimori, Nana
AU - Oguchi, Jun
AU - Tamura, Hiroomi
N1 - Funding Information:
This work was supported by a grant from the Japan Society for the Promotion of Science KAKENHI [grants number 15K00883 and 16K18957 ] to HT and YN, and by a grant from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT)-supported program for Strategic Research Foundation at Private Universities.
Publisher Copyright:
© 2017 Elsevier Masson SAS
PY - 2017/11
Y1 - 2017/11
N2 - To prevent lens opacification and cataract formation, the lens contains α-crystallin, which has been shown to function as a molecular chaperone that maintains the correct folding of other proteins. Oxidative stress is known to be an important factor in the initiation and progression of a cataract. So far, several antioxidant compounds have been reported to prevent cataracts in vivo and in vitro. This stress also triggers α-crystallin modifications and alters its chaperone activity. However, few studies have examined the relationship between the consumption of antioxidant compounds and lens chaperone activity. To elucidate the effect of antioxidants on lens chaperone activity, antioxidants were administered to a selenite-induced cataract model of rats. The chaperone activity in lens water-soluble fraction was measured using aldehyde dehydrogenase. All antioxidant treatment groups, except decaffeinated coffee treatment, had less severe central opacities and lower stage cataracts than control groups. The chaperone activity was weaker in lens of selenite cataract rats, but antioxidant compounds and coffee treatment can prevent the chaperone activity decreasing, but not decaffeinated coffee. These results suggested that the treatment with antioxidant compounds could prevent cataract formation by the maintenance of the chaperone activity in water-soluble lens proteins. Thus, this study describes the development of an anticataract drug target for lens chaperone activity.
AB - To prevent lens opacification and cataract formation, the lens contains α-crystallin, which has been shown to function as a molecular chaperone that maintains the correct folding of other proteins. Oxidative stress is known to be an important factor in the initiation and progression of a cataract. So far, several antioxidant compounds have been reported to prevent cataracts in vivo and in vitro. This stress also triggers α-crystallin modifications and alters its chaperone activity. However, few studies have examined the relationship between the consumption of antioxidant compounds and lens chaperone activity. To elucidate the effect of antioxidants on lens chaperone activity, antioxidants were administered to a selenite-induced cataract model of rats. The chaperone activity in lens water-soluble fraction was measured using aldehyde dehydrogenase. All antioxidant treatment groups, except decaffeinated coffee treatment, had less severe central opacities and lower stage cataracts than control groups. The chaperone activity was weaker in lens of selenite cataract rats, but antioxidant compounds and coffee treatment can prevent the chaperone activity decreasing, but not decaffeinated coffee. These results suggested that the treatment with antioxidant compounds could prevent cataract formation by the maintenance of the chaperone activity in water-soluble lens proteins. Thus, this study describes the development of an anticataract drug target for lens chaperone activity.
KW - Anticataract
KW - Antioxidant
KW - Chaperone activity
KW - Lens proteins
UR - http://www.scopus.com/inward/record.url?scp=85027864996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027864996&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2017.08.055
DO - 10.1016/j.biopha.2017.08.055
M3 - Article
C2 - 28837880
AN - SCOPUS:85027864996
SN - 0753-3322
VL - 95
SP - 137
EP - 143
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
ER -